UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$950M |
| 2 |
Linde
LIN
|
+$886M |
| 3 |
Amgen
AMGN
|
+$812M |
| 4 |
Pinduoduo
PDD
|
+$400M |
| 5 |
Advanced Micro Devices
AMD
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ametek
AME
|
+$475M |
| 2 |
Microsoft
MSFT
|
+$266M |
| 3 |
Amazon
AMZN
|
+$221M |
| 4 |
VMW
VMware, Inc
VMW
|
+$197M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.09% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.11% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
Anterix
ATEX
$1.94B
| $452K | ﹤0.01% |
13,692
+1,749
| +15% | +$57.3K |
|
|
TELL
2302
DELISTED
Tellurian Inc.
TELL
| $452K | ﹤0.01% |
367,654
-118,168
| -24% | -$188K |
|
2303
Banc of California
BANC
$2.97B
| $449K | ﹤0.01% |
35,825
-9,740
| -21% | -$157K |
|
2304
Occidental Petroleum Corp Warrants
OXY.WS
$32B
| $448K | ﹤0.01% |
10,937
| – | – |
|
|
TSVT
2305
DELISTED
2seventy bio
TSVT
| $447K | ﹤0.01% |
43,868
-3,369
| -7% | -$38.5K |
|
2306
German American Bancorp
GABC
$1.9B
| $442K | ﹤0.01% |
13,250
-12,284
| -48% | -$457K |
|
2307
UWM Holdings
UWMC
$434M
| $441K | ﹤0.01% |
89,830
| – | – |
|
2308
N-able
NABL
$940M
| $440K | ﹤0.01% |
+33,311
| New | +$368K |
|
|
TBRG
2309
DELISTED
TruBridge
TBRG
| $439K | ﹤0.01% |
14,550
| – | – |
|
2310
Transcat
TRNS
$871M
| $438K | ﹤0.01% |
4,900
+700
| +17% | +$59.6K |
|
2311
BJ's Restaurants
BJRI
$1.48B
| $436K | ﹤0.01% |
14,972
| – | – |
|
2312
OneSpaWorld
OSW
$2.66B
| $426K | ﹤0.01% |
35,566
| – | – |
|
|
MRSN
2313
DELISTED
Mersana Therapeutics
MRSN
| $422K | ﹤0.01% |
4,103
| – | – |
|
|
GOOD
2314
Gladstone Commercial Corp
GOOD
$627M
| $418K | ﹤0.01% |
33,095
+4,588
| +16% | +$69.7K |
|
|
TVRD
2315
Tvardi Therapeutics
TVRD
$23.4M
| $414K | ﹤0.01% |
2,344
| – | – |
|
2316
Bilibili
BILI
$7.84B
| $413K | ﹤0.01% |
+17,572
| New | +$418K |
|
2317
Harmony Biosciences
HRMY
$2.24B
| $412K | ﹤0.01% |
12,619
-18,481
| -59% | -$842K |
|
|
SEMR
2318
DELISTED
Semrush
SEMR
| $412K | ﹤0.01% |
40,990
| – | – |
|
|
FNA
2319
DELISTED
Paragon 28, Inc.
FNA
| $410K | ﹤0.01% |
24,042
| – | – |
|
2320
The RMR Group
RMR
$332M
| $408K | ﹤0.01% |
15,563
+2,381
| +18% | +$66.7K |
|
2321
Ambev
ABEV
$46.4B
| $408K | ﹤0.01% |
144,750
-3,500
| -2% | -$9.16K |
|
2322
Nano X Imaging
NNOX
$73.8M
| $406K | ﹤0.01% |
70,286
+8,742
| +14% | +$66.8K |
|
2323
Arcturus Therapeutics
ARCT
$211M
| $405K | ﹤0.01% |
+16,895
| New | +$303K |
|
|
MRUS
2324
DELISTED
Merus
MRUS
| $403K | ﹤0.01% |
21,928
| – | – |
|
2325
ANI Pharmaceuticals
ANIP
$1.78B
| $403K | ﹤0.01% |
10,153
+5,061
| +99% | +$213K |
|
Similar funds
UBS AM's Q1 2023 Portfolio in Review
As of Q1 2023, UBS AM held 2,762 positions worth $206B, up 8.3% from $191B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
UBS AM's Q1 2023 filing shows 231 new, 1,328 increased, 856 reduced and 85 closed positions. Its largest new stake was Amgen: 3,308,425 shares worth $800M. The largest sale was Ametek, an estimated $475M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q1 2023 buy was Amgen: 3,308,425 shares worth $800M.
- UBS AM added most to Abbott in Q1 2023, an estimated $950M increase.
- UBS AM's biggest Q1 2023 reduction was Ametek, cutting an estimated $475M.
- UBS AM fully exited SVB Financial Group in Q1 2023, selling an estimated $77.3M.
- UBS AM's ten largest holdings make up 22% of its $206B portfolio in Q1 2023.
- UBS AM opened 231 new positions and closed 85 in Q1 2023.
- UBS AM's portfolio value rose 8.3% quarter-over-quarter to $206B.
Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.